MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • MDS Virtual Congress 2020

    Management of parkinsonian patients with long-term DBS and incomplete control of symptoms

    I. Reuter (Giessen, Germany)

    Objective: We want to evaluate if apomorphine infusions can improve symptom control in PD patients with long standing DBS and functional decline. Background: Deep brain stimulation…
  • MDS Virtual Congress 2020

    Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience

    F. Rodríguez Jorge, A. Beltrán Corbellini, P. Parra Díaz, J.L Chico García, J. Pagonabarraga Mora, B. Baena Álvarez, I. Parées Moreno, J.L López-Sendón, P. Pérez Torre, J.C Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

    Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…
  • MDS Virtual Congress 2020

    Dyskinesia and bradykinesia severity patterns in Parkinson’s disease using a wearable sensor

    D. van Wamelen, T. Bendriss-Otiko, A. Podlewska, V. Leta, C. Lazcano Ocampo, D. Trivedi, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To determine if dyskinesia and bradykinesia severity has a diurnal pattern in Parkinson’s disease (PD) using wearable sensor data. Background: Diurnal fluctuations in PD…
  • MDS Virtual Congress 2020

    A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients

    M.S Sforza, F.E Pontieri, D.R Rinaldi, E.B Bianchini (Rome, Italy)

    Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…
  • 2019 International Congress

    BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

    W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

    Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…
  • 2019 International Congress

    Real-life gait performance as a marker for motor fluctuations: the Parkinson@home Validation study

    L. Evers, J. Raykov, R. Badawy, K. Claes, M. Meinders, J. Krijthe, T. Heskes, M. Little, B. Bloem (Nijmegen, Netherlands)

    Objective: To assess the feasibility of using real-life gait performance derived from a single wearable as a marker for motor fluctuations in Parkinson’s disease (PD).…
  • 2019 International Congress

    Addition of Opicapone to Safinamide in Parkinson’s Disease patients

    M. Russo, C. Carrarini, F. Dono, M. Di Pietro, M. Rispoli, L. Ferri, M. Onofrj (Chieti, Italy)

    Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…
  • 2019 International Congress

    Motor Responses to Apomorphine Sublingual Film Compared With Levodopa in Patients With Parkinson’s Disease and “OFF” Episodes: Post Hoc Analysis From a Phase 3 Study

    J. Hui, S. Fox, W. Neeson, P. Bhargava, E. Pappert, D. Blum, B. Navia (Los Angeles, CA, USA)

    Objective: To compare time to onset and magnitude of motor improvement following administration of apomorphine sublingual film (APL-130277; APL) vs levodopa in patients with Parkinson’s…
  • 2019 International Congress

    Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

    K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

    Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…
  • 2019 International Congress

    Correlation Between PDQ-39 and MDS-UPDRS Scores in a Phase 3 Randomized Controlled Trial of Patients with Parkinson’s Disease

    T. Lokhandwala, A. Lee, B. Yue, A. Thach, B. Navia (Palm Harbor, FL, USA)

    Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley